Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 1.00 |
| ▸ | TLR8 | Q9NR97 | 15/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21836728 | 1.00 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL21836727 | 1.00 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL20983648 | 1.00 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL21836730 | 1.00 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL21836724 | 1.00 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL20983658 | 1.00 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL20983693 | 1.00 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL20766720 | 1.00 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL21836725 | 1.00 | TLR7 (1.00) | TLR7TLR8 | |
| SCHEMBL20983645 | 1.00 | TLR7 (1.00) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11981670-B2 | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4257198-A2 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE DERIVATIVES AS TLR7/8 AGONISTS AND USES THEREOF | Dynavax Technologies Corporation (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-4257198-A2 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE DERIVATIVES AS TLR7/8 AGONISTS AND USES THEREOF | Dynavax Technologies Corporation (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3672969-B1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE DERIVATIVES AS TLR7/8 AGONISTS AND USES THEREOF | DYNAVAX TECH CORP (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3672969-B1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE DERIVATIVES AS TLR7/8 AGONISTS AND USES THEREOF | DYNAVAX TECH CORP (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20220033400-A1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2022-02-03 | — | — | US | disclosed |
| US-20220033400-A1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2022-02-03 | — | — | US | disclosed |
| US-11124510-B2 | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2021-09-21 | — | — | US | disclosed |
| US-11124510-B2 | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200199124-A1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2020-06-25 | — | — | US | disclosed |
| US-20200199124-A1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2020-06-25 | — | — | US | disclosed |
| US-10618896-B2 | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2020-04-14 | — | — | US | disclosed |
| US-10618896-B2 | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2020-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11981670-B2 | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof | TLR7, TLR8, TLR3 | TLR7 1/4885TLR8 2/4885 |
| US-20200199124-A1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | TLR7, TLR8, TLR3 | TLR7 1/4885TLR8 2/4885 |
| US-11124510-B2 | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof | TLR7, TLR8, TLR3 | TLR7 1/4885TLR8 2/4885 |
| US-20220033400-A1 | ALKYL CHAIN MODIFIED IMIDAZOQUINOLINE TLR7/8 AGONIST COMPOUNDS AND USES THEREOF | TLR7, TLR8, TLR3 | TLR7 1/4885TLR8 2/4885 |
| US-10618896-B2 | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof | TLR7, TLR8, TLR3 | TLR7 1/4885TLR8 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.